{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.32","value":"7.63"}]}],"title":"Prior to dosing at Week 2 (n:43)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.35","value":"7.72"}]}],"title":"Prior to dosing Week 4 (n:44)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.75","value":"8.79"}]}],"title":"Prior to dosing Week 12 (n:49)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.83","value":"9.37"}]}],"title":"Prior to dosing Week 24 (n:46)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.01","value":"11.49"}]}],"title":"Prior to dosing Week 48 (n:15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"Cmin values collected prior to dose administration on the same study day and at 20-28 hours after previous dose, at steady state, and patient did not vomit within 4 hours of previous dose. Samples collected during the first 4 days of dosing were excluded from all analyses.","dispersionType":"Standard Deviation","groups":[{"description":"Study drug was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG000","title":"Everolimus Randomized (Core Period)"}],"paramType":"MEAN","populationDescription":"The analysis was performed in the Safety Set population for patients treated only with Everolimus and with a confirmed PK sample.","reportingStatus":"POSTED","timeFrame":"Prior to dosing at weeks 2, 4, 12, 24, 48","title":"Everolimus Trough Concentrations (Cmin)","type":"SECONDARY","unitOfMeasure":"ng/mL"}